Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ISA101b + Utomilumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ISA101b | ISA-101b|ISA 101b | ISA101b is an HPV16 vaccine comprised of a peptide string that includes the E6 and E7 HPV proteins and T cell epitopes, allowing for T-cell activation, and may result in antitumor activity (PMID: 27669306). | ||
Utomilumab | PF-05082566|PF05082566 | TNFRSF9 Antibody 32 | Utomilumab (PF-05082566) is an activating monoclonal antibody that targets and antagonizes CD137 (4-1BB), potentially resulting in increased immune response against tumor cells (PMID: 27369047, PMID: 32144134). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03258008 | Phase II | ISA101b + Utomilumab | Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer | Terminated | USA | 0 |